Thalagen is under clinical development by San Rocco Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Thalagen’s likelihood of approval (LoA) and phase transition for Beta Thalassaemia took place on 18 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Thalagen Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Thalagen overview

Thalagen is under development for the treatment of beta-thalassemia. It is administered through the intravenous route. The therapeutic candidate comprises autologous CD34 positive hematopoietic progenitor cells transduced with TNS9.3.55, a lentiviral vector encoding the normal human beta-globin gene.

San Rocco Therapeutics overview

San Rocco Therapeutics (SRT) formerly known as Errant Gene Therapeutics is a healthcare solutions provider. The company develops treatments for life-threatening diseases. It offers therapies for the treatment of lou gehrig’s disease, huntington’s disease, cystic fibrosis, sickle cell anemia and thalassemia.SRT’s thalagen and CG-1521 products are developed for the treatment of the blood disorder thalassemia and refractory prostate cancer. The company’s CG-1521 is an inhibitor of histone deacetylase and represents a treatment paradigm for therapy resistant prostate cancer. It also develops pharmaceutical products for cancer and blood disorders. The company operates its offices in Chicago, Woodland Hills and New York, the US and operates subsidiary in Italy.SRT is headquartered in Chicago, Illinois, the US.

Quick View Thalagen LOA Data

Report Segments
  • Innovator
Drug Name
  • Thalagen
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Hematological Disorders
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.